Randomised Pharmacokinetic Trial of Rifabutin with Lopinavir/Ritonavir-Antiretroviral Therapy in Patients with HIV-Associated Tuberculosis in Vietnam
暂无分享,去创建一个
N. H. Duc | A. Harries | C. Connolly | A. Pym | N. Dung | N. Lan | C. Lienhardt | A. Barrail-Tran | A. Taburet | D. Laureillard | C. Quillet | L. Borand | N. Thu | D. Lagarde | Truong Thi Xuan Lien
[1] N. H. Duc,et al. The ethics of a clinical trial when the protocol clashes with international guidelines. , 2013, Public health action.
[2] A. Matteelli,et al. Lopinavir pharmacokinetic profiles in HIV-infected patients during rifabutin-based anti-mycobacterial therapy. , 2012, The Journal of antimicrobial chemotherapy.
[3] Anneke Grobler,et al. Integration of antiretroviral therapy with tuberculosis treatment. , 2011, The New England journal of medicine.
[4] Lerato Mohapi,et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. , 2011, The New England journal of medicine.
[5] S. Vong,et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. , 2011, The New England journal of medicine.
[6] R. Bertz,et al. Determination of rifabutin dosing regimen when administered in combination with ritonavir-boosted atazanavir. , 2011, The Journal of antimicrobial chemotherapy.
[7] Xiaoping Zhang,et al. Pharmacokinetic Interaction Study of Ritonavir-Boosted Saquinavir in Combination with Rifabutin in Healthy Subjects , 2010, Antimicrobial Agents and Chemotherapy.
[8] T. van de Casteele,et al. Pharmacokinetics of Darunavir/Ritonavir and Rifabutin Coadministered in HIV-Negative Healthy Volunteers , 2010, Antimicrobial Agents and Chemotherapy.
[9] S. Lawn,et al. The HIV-associated tuberculosis epidemic—when will we act? , 2010, The Lancet.
[10] C. Peloquin,et al. Pharmacokinetic evaluation of rifabutin in combination with lopinavir-ritonavir in patients with HIV infection and active tuberculosis. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[11] C. Orkin,et al. Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection. , 2009, The Journal of antimicrobial chemotherapy.
[12] E. Jenny-Avital,et al. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[13] M. Shelton,et al. Pharmacokinetic Interaction between Fosamprenavir-Ritonavir and Rifabutin in Healthy Subjects , 2007, Antimicrobial Agents and Chemotherapy.
[14] G. Drusano,et al. Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by Rifampin , 2007, Antimicrobial Agents and Chemotherapy.
[15] T. Hodge,et al. Association between acquired rifamycin resistance and the pharmacokinetics of rifabutin and isoniazid among patients with HIV and tuberculosis. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[16] J. Bartlett. Updated Guidelines for Use of Rifamycins for the Treatment of Tuberculosis Among HIV-Infected Patients Taking Protease Inhibitors or Nonnucleoside Reverse Transcriptase Inhibitors , 2004 .
[17] F. Clavel,et al. Interactions Between Amprenavir and the Lopinavir‐ritonavir Combination in Heavily Pretreated Patients Infected with Human Immunodeficiency Virus , 2004, Clinical pharmacology and therapeutics.
[18] E. Kantharaj,et al. Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis , 2003, Antimicrobial Agents and Chemotherapy.
[19] T. Self,et al. Update on Rifampin and Rifabutin Drug Interactions , 2003, The American journal of the medical sciences.
[20] M. E. Villarino. Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus; principles of therapy and revised recommendations , 1998 .
[21] D. Mitchison,et al. Laboratory aspects of intermittent drug therapy , 1971, Postgraduate medical journal.
[22] C. Dolea,et al. World Health Organization , 1949, International Organization.
[23] P. Glaziou,et al. Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach? , 2012, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.
[24] U. Unicef,et al. Global HIV/AIDS response: epidemic update and health sector progress towards universal access: progress report 2011. , 2011 .
[25] B. Stilwell,et al. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. 2006 revision. , 2006 .
[26] W. Burman,et al. Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials , 2001, Clinical pharmacokinetics.